{"id":"lobeglitazone","rwe":[{"pmid":"41856597","year":"2026","title":"Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study.","finding":"","journal":"BMJ open","studyType":"Clinical Study"},{"pmid":"41366590","year":"2026","title":"Sodium-glucose cotransporter 2 inhibitor ameliorates thiazolidinedione-induced fluid retention through vascular leakage reduction in white adipose tissue.","finding":"","journal":"Diabetes, obesity & metabolism","studyType":"Clinical Study"},{"pmid":"41347545","year":"2026","title":"From Separation to Safety Prediction: Validated RP-HPLC Method for Simultaneous Estimation of Sitagliptin and Lobeglitazone, LC-MS/MS Identification of Degradant Products, and In Silico Safety Profiling.","finding":"","journal":"Biomedical chromatography : BMC","studyType":"Clinical Study"},{"pmid":"41236870","year":"2026","title":"Lobeglitazone improves glycaemic control as add-on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double-blind, randomised, placebo-controlled trial.","finding":"","journal":"Diabetes, obesity & metabolism","studyType":"Clinical Study"},{"pmid":"40726438","year":"2025","title":"Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial.","finding":"","journal":"Diabetes, obesity & metabolism","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Peroxisome proliferator-activated receptor gamma","category":"target"},{"label":"PPARG","category":"gene"},{"label":"PPARA","category":"gene"},{"label":"A10BD26","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Chong Kun Dang","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Chong Kun Dang","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LOBEGLITAZONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:03:11.336377+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:03:17.967521+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LOBEGLITAZONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:03:19.027156+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3585580/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:03:19.496239+00:00"}},"allNames":"duvie","offLabel":[],"synonyms":["lobeglitazone","lobeglitazone sulfate","CKD-501","duvie"],"timeline":[{"date":"2013-07-04","type":"positive","source":"DrugCentral","milestone":"Korean Food and Drug Administration (KFDA) approval (Chong Kun Dang)"}],"approvals":[{"date":"2013-07-04","orphan":false,"company":"Chong Kun Dang","regulator":"Korean Food and Drug Administration (KFDA)"}],"brandName":"Duvie","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Peroxisome proliferator-activated receptor gamma","targets":[{"gene":"PPARG","source":"DrugCentral","target":"Peroxisome proliferator-activated receptor gamma","protein":"Peroxisome proliferator-activated receptor gamma"},{"gene":"PPARA","source":"DrugCentral","target":"Peroxisome proliferator-activated receptor alpha","protein":"Peroxisome proliferator-activated receptor alpha"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Duvie acts as a PPAR-γ agonist, binding to the receptor and activating its transcriptional activity, which in turn regulates the expression of genes involved in glucose and lipid metabolism."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5078","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LOBEGLITAZONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LOBEGLITAZONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:08:23.950371","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:03:21.460530+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"metformin","drugSlug":"metformin","fdaApproval":"1995-03-03","patentExpiry":"May 1, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rosiglitazone","drugSlug":"rosiglitazone","fdaApproval":"1999-05-25","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glimepiride","drugSlug":"glimepiride","fdaApproval":"1995-11-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pioglitazone","drugSlug":"pioglitazone","fdaApproval":"1999-07-15","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sitagliptin","drugSlug":"sitagliptin","fdaApproval":"2006-10-16","patentExpiry":"Feb 25, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"alogliptin","drugSlug":"alogliptin","fdaApproval":"2013-01-25","patentExpiry":"Jun 27, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"saxagliptin","drugSlug":"saxagliptin","fdaApproval":"2009-07-31","patentExpiry":"Nov 30, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"linagliptin","drugSlug":"linagliptin","fdaApproval":"2011-05-02","patentExpiry":"Sep 5, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"lobeglitazone","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"metformin","brandName":"metformin","genericName":"metformin","approvalYear":"1995","relationship":"same-class"},{"drugId":"rosiglitazone","brandName":"rosiglitazone","genericName":"rosiglitazone","approvalYear":"1999","relationship":"same-class"},{"drugId":"glimepiride","brandName":"glimepiride","genericName":"glimepiride","approvalYear":"1995","relationship":"same-class"},{"drugId":"pioglitazone","brandName":"pioglitazone","genericName":"pioglitazone","approvalYear":"1999","relationship":"same-class"},{"drugId":"sitagliptin","brandName":"sitagliptin","genericName":"sitagliptin","approvalYear":"2006","relationship":"same-class"},{"drugId":"alogliptin","brandName":"alogliptin","genericName":"alogliptin","approvalYear":"2013","relationship":"same-class"},{"drugId":"saxagliptin","brandName":"saxagliptin","genericName":"saxagliptin","approvalYear":"2009","relationship":"same-class"},{"drugId":"linagliptin","brandName":"linagliptin","genericName":"linagliptin","approvalYear":"2011","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07304687","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-10-24","conditions":["Type 2 Diabetes"],"enrollment":31,"completionDate":"2025-11-22"},{"nctId":"NCT07304726","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-10-30","conditions":["Type 2 Diabetes"],"enrollment":30,"completionDate":"2025-11-23"},{"nctId":"NCT07304700","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-10-28","conditions":["Type 2 Diabetes"],"enrollment":30,"completionDate":"2025-11-12"},{"nctId":"NCT07108985","phase":"PHASE4","title":"Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-09","conditions":["Diabetes Mellitus, Type 2","Hyperglycemia","Insulin Resistance"],"enrollment":100,"completionDate":"2030-08-31"},{"nctId":"NCT07056517","phase":"PHASE1","title":"Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults","status":"RECRUITING","sponsor":"Aclipse Two Inc.","startDate":"2025-07-11","conditions":["Healthy"],"enrollment":24,"completionDate":"2025-09-02"},{"nctId":"NCT06492655","phase":"PHASE1","title":"To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-07-04","conditions":["Type 2 Diabetes Mellitus"],"enrollment":28,"completionDate":"2024-08-08"},{"nctId":"NCT06483243","phase":"PHASE1","title":"Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-04-04","conditions":["Type 2 Diabetes Mellitus"],"enrollment":45,"completionDate":"2024-05-17"},{"nctId":"NCT05816759","phase":"PHASE1","title":"Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-05-26","conditions":["Type 2 Diabetes"],"enrollment":32,"completionDate":"2023-06-22"},{"nctId":"NCT05897216","phase":"PHASE1","title":"Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-07-14","conditions":["Type 2 Diabetes"],"enrollment":30,"completionDate":"2023-08-08"},{"nctId":"NCT05915949","phase":"PHASE4","title":"Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-01-01","conditions":["Diabetes Type 2"],"enrollment":99,"completionDate":"2023-12-31"},{"nctId":"NCT05113693","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-11-25","conditions":["Type 2 Diabetes"],"enrollment":33,"completionDate":"2021-12-10"},{"nctId":"NCT05347576","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-04-21","conditions":["Type2Diabetes"],"enrollment":31,"completionDate":"2022-05-09"},{"nctId":"NCT03770052","phase":"PHASE4","title":"Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2018-10-24","conditions":["Type 2 Diabetes Mellitus","Inadequate Glucose Control"],"enrollment":159,"completionDate":"2021-09-13"},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":["Type 2 Diabetes"],"enrollment":78,"completionDate":"2021-12-31"},{"nctId":"NCT05043467","phase":"","title":"Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-01-02","conditions":["Type2 Diabetes"],"enrollment":2228,"completionDate":"2020-06-19"},{"nctId":"NCT03739125","phase":"PHASE3","title":"Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-11-07","conditions":["Type2 Diabetes"],"enrollment":226,"completionDate":"2020-12-02"},{"nctId":"NCT04869800","phase":"PHASE1","title":"Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-05-27","conditions":["Type 2 Diabetes Mellitus"],"enrollment":32,"completionDate":"2021-06-15"},{"nctId":"NCT04768673","phase":"PHASE1","title":"A Study to Investigate the PK and Safety of CKD-393","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-03-26","conditions":["Type II Diabetes"],"enrollment":26,"completionDate":"2021-04-27"},{"nctId":"NCT04810676","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-04-16","conditions":["Type2 Diabetes Mellitus"],"enrollment":27,"completionDate":"2021-05-26"},{"nctId":"NCT04260438","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-04-08","conditions":["Diabetes Mellitus, Type 2"],"enrollment":24,"completionDate":"2020-06-24"},{"nctId":"NCT02315287","phase":"PHASE4","title":"Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-09","conditions":["Type 2 Diabetes"],"enrollment":190,"completionDate":"2021-12-31"},{"nctId":"NCT04706286","phase":"PHASE1","title":"Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-02-18","conditions":["T2DM (Type 2 Diabetes Mellitus)"],"enrollment":26,"completionDate":"2021-04-05"},{"nctId":"NCT04431687","phase":"PHASE1","title":"A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-06-15","conditions":["Type 2 Diabetes Mellitus"],"enrollment":48,"completionDate":"2020-10-26"},{"nctId":"NCT04334213","phase":"PHASE1","title":"A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-05-07","conditions":["Type 2 Diabetes"],"enrollment":48,"completionDate":"2020-08-05"},{"nctId":"NCT04246190","phase":"PHASE1","title":"A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-02-24","conditions":["Type2 Diabetes Mellitus"],"enrollment":26,"completionDate":"2020-07-16"},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":["Type 2 Diabetes"],"enrollment":200,"completionDate":"2018-09"},{"nctId":"NCT03616392","phase":"PHASE1","title":"Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-07-25","conditions":["Diabetes Mellitus, Type II"],"enrollment":41,"completionDate":"2018-11-13"},{"nctId":"NCT03641352","phase":"PHASE3","title":"The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-05-02","conditions":["Type2 Diabetes"],"enrollment":240,"completionDate":"2022-11-30"},{"nctId":"NCT03627182","phase":"PHASE3","title":"Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-04-26","conditions":["Type2 Diabetes"],"enrollment":240,"completionDate":"2023-02-10"},{"nctId":"NCT02827890","phase":"PHASE1","title":"CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2016-04","conditions":["Diabetes Mellitus Type 2"],"enrollment":20,"completionDate":"2016-05"},{"nctId":"NCT02007941","phase":"PHASE1","title":"Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-04","conditions":["Renal Impairment","Healthy"],"enrollment":28,"completionDate":"2015-04"},{"nctId":"NCT02854748","phase":"PHASE1","title":"Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2016-08","conditions":["Diabetes Mellitus, Type II"],"enrollment":30,"completionDate":"2016-09"},{"nctId":"NCT02824874","phase":"PHASE1","title":"CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2016-04","conditions":["Diabetes Mellitus, Type II"],"enrollment":20,"completionDate":"2016-05"},{"nctId":"NCT02005744","phase":"PHASE1","title":"A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-03","conditions":["Liver Dysfunction"],"enrollment":26,"completionDate":"2016-02"},{"nctId":"NCT02648854","phase":"PHASE1","title":"Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-10","conditions":["Diabetes Mellitus, Type II"],"enrollment":26,"completionDate":"2015-11"},{"nctId":"NCT02285205","phase":"PHASE4","title":"A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2014-11","conditions":["Type 2 Diabetes","Non-alcoholic Fatty Liver Disease"],"enrollment":38,"completionDate":"2015-11"},{"nctId":"NCT02627027","phase":"PHASE1","title":"A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-08","conditions":["Diabetes Mellitus, Type II"],"enrollment":26,"completionDate":"2015-09"},{"nctId":"NCT02565368","phase":"PHASE1","title":"A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-07","conditions":["Diabetes Mellitus, Type II"],"enrollment":26,"completionDate":"2015-08"},{"nctId":"NCT02480465","phase":"PHASE4","title":"Efficacy and Safety of Lobeglitazone Versus Sitagliptin","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":248,"completionDate":"2017-03"},{"nctId":"NCT02002611","phase":"PHASE1","title":"Drug-drug Interaction Study(Lobeglitazone, Warfarin)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2013-12","conditions":["Type 2 Diabetes Mellitus"],"enrollment":24,"completionDate":"2014-05"},{"nctId":"NCT01001611","phase":"PHASE3","title":"An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2009-10","conditions":["Diabetes Mellitus, Type 2"],"enrollment":173,"completionDate":"2012-01"},{"nctId":"NCT01106131","phase":"PHASE3","title":"Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2010-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":253,"completionDate":"2012-11"},{"nctId":"NCT01341392","phase":"PHASE1","title":"Drug-drug Interaction Study(CKD-501, Amlodipine)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2011-04","conditions":["Type 2 Diabetes Mellitus"],"enrollment":25,"completionDate":"2011-08"},{"nctId":"NCT01330563","phase":"PHASE1","title":"Drug-drug Interaction Study (CKD-501, Ketoconazole)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2011-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":24,"completionDate":"2011-06"},{"nctId":"NCT01005160","phase":"PHASE1","title":"Drug Interaction Between CKD-501 and Metformin","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2009-10","conditions":["Healthy Male Volunteers"],"enrollment":24,"completionDate":"2010-02"},{"nctId":"NCT01133431","phase":"PHASE1","title":"The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2010-05","conditions":["Healthy Male Volunteer"],"enrollment":24,"completionDate":"2010-08"},{"nctId":"NCT01071720","phase":"PHASE1","title":"The Effect of Food on the Pharmacokinetic Characteristics of CKD-501","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2010-03","conditions":["Healthy"],"enrollment":24,"completionDate":"2010-08"},{"nctId":"NCT01030679","phase":"PHASE2","title":"Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2007-07","conditions":["Diabetes Mellitus, Type 2"],"enrollment":214,"completionDate":"2008-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"MY89F08K5D","CHEBI":"CHEBI:136052","INN_ID":"8729","UMLSCUI":"C2744790","chemblId":"CHEMBL3585580","ChEMBL_ID":"CHEMBL3585580","DRUGBANK_ID":"DB09198","PDB_CHEM_ID":" 8LX","PUBCHEM_CID":"9826451","SECONDARY_CAS_RN":"763108-62-9","MESH_SUPPLEMENTAL_RECORD_UI":"C546215"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Chong Kun Dang","relationship":"Original Developer"}],"publicationCount":79,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BD26","allCodes":["A10BD26","A10BG04"]},"biosimilarFilings":[],"originalDeveloper":"Chong Kun Dang","recentPublications":[{"date":"2026 Mar 19","pmid":"41856597","title":"Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study.","journal":"BMJ open"},{"date":"2026 Mar","pmid":"41366590","title":"Sodium-glucose cotransporter 2 inhibitor ameliorates thiazolidinedione-induced fluid retention through vascular leakage reduction in white adipose tissue.","journal":"Diabetes, obesity & metabolism"},{"date":"2026 Jan","pmid":"41347545","title":"From Separation to Safety Prediction: Validated RP-HPLC Method for Simultaneous Estimation of Sitagliptin and Lobeglitazone, LC-MS/MS Identification of Degradant Products, and In Silico Safety Profiling.","journal":"Biomedical chromatography : BMC"},{"date":"2026 Jan","pmid":"41236870","title":"Lobeglitazone improves glycaemic control as add-on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double-blind, randomised, placebo-controlled trial.","journal":"Diabetes, obesity & metabolism"},{"date":"2025 Oct","pmid":"40726438","title":"Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial.","journal":"Diabetes, obesity & metabolism"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Chong Kun Dang","companyId":"chong-kun-dang","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Duvie is a small molecule medication used to treat type 2 diabetes mellitus. It is often studied in combination with other medications, such as Januvia, in clinical trials.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"Korean Food and Drug Administration (KFDA)","status":"approved","approval_date":"2013-07-04T00:00:00.000Z","mah":"Chong Kun Dang","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:03:21.460530+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}